

Award Number: W81XWH-11-1-0309

TITLE: Targeting the Human Complement Membrane Attack Complex to Selectively Kill Prostate Cancer Cells

PRINCIPAL INVESTIGATOR: Samuel R. Denmeade, MD

CONTRACTING ORGANIZATION:
Johns Hopkins University, East Baltimore Campus
Baltimore, MD 21205

REPORT DATE: October2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2012		2. REPORT TYPE Annual		3. DATES COVERED 30September2011- 29September2012	
4. TITLE AND SUBTITLE Targeting the Human Complement Membrane Attack Complex to Selectively Kill Prostate Cancer Cells				5a. CONTRACT NUMBER .	
				5b. GRANT NUMBER W81XWH-11-1-0309	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Samuel R. Denmeade E-Mail: denmesa@jhmi.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University, East Baltimore Campus Baltimore, MD 21205				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of this proposal is to develop a strategy to redirect the toxicity of a human protein to sites of prostate cancer. Our hypothesis is that the human C5 complement protein can be modified to a form that is not activated by the normal complement pathways but is instead activated by the prostate cancer specific protease PSA. This strategy would allow us to selectively unleash the potent cytolytic activity of the human complement Membrane Attack Complex (MAC) within sites of metastatic prostate cancer while sparing normal host tissue due to the finely tuned regulation of complement activity in the circulation. A series of PSA-activated modified C5 proteins were generated and characterized for PSA activation. While initial studies suggested that wild type C5 was stable in the presence of PSA, further characterization demonstrated that both the wild type and modified C5 proteins were extensively cleaved and degraded by PSA. Thus, while PSA could cleave the engineered cleavage site within the modified protein, it also cleaved the protein at multiple off-target sites. PSA was able to inactivate complement fixation and MAC formation through degradation of wild type C5 suggesting a potential role for PSA in regulation of complement activity within prostate cancer. Based on the finding of PSA degradation of C5, we are now exploring whether alternative proteases selectively overexpressed in prostate cancers such as human glandular kallikrein 2, TMPRSS2 and fibroblast activation protein (FAP) can be targeted to activate a modified C5 protein using the same strategy we have outlined for the PSA studies. These new modified C5 proteins will be evaluated for appropriate cleavage at the engineered site and for selective toxicity.					
15. SUBJECT TERMS Prostate cancer, protoxin, prodrug, PSA, FAP, complement, targeted therapy					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU		19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	8
References.....	9
Appendix.....	10

Introduction: The goal of this proposal is to develop a strategy to redirect the toxicity of a human protein to sites of prostate cancer. Our hypothesis is that the human C5 complement protein can be modified to a form that is not activated by the normal complement pathways but is instead activated by the prostate cancer specific protease PSA. This strategy would allow us to selectively unleash the potent cytolytic activity of the human complement Membrane Attack Complex (MAC) within sites of metastatic prostate cancer while sparing normal host tissue due to the finely tuned regulation of complement activity in the circulation. One advantage of this strategy is that activation results in generation of the MAC within the extracellular fluid (ECF) bathing the prostate cancer cells leading to the lytic death of PSA-producing prostate cancer cells as well as a significant bystander effect and killing of non-PSA producing cancer cells, endothelial cells and fibroblasts that are also bathed in PSA in the ECF. This strategy is predicated by the observation that PSA is completely INACTIVE in the blood of prostate cancer patients. Thus, PAC5 proteins can be administered systemically without activation in the blood of patients with high serum PSA levels. Finally, any of the MAC components (i.e. C5b-C6-C7 complex) that may leak out of the tumor activation site into the circulation will be rapidly inactivated by high levels of circulating, soluble vitronectin (i.e. S-protein) thus limiting complement deposition and toxicity within normal tissues.

Specific Aims: To accomplish the goals of this application we propose the following aims:

Aim 1: Replace the C5 convertase activation sequence within the wild type C5 with a PSA-selective substrate sequences using site directed mutagenesis and amend a purification tag to the terminus of the modified C5 protein to aid in its purification.

Aim 2: Demonstrate that the PAC5 proteins can be hydrolyzed by PSA and demonstrate that the modified C5b fragment maintains the ability to generate the Membrane Attack Complex (MAC).

Aim 3: Demonstrate PAC5's selective toxicity to PSA producing prostate cancer cells but not PSA-null prostate cancer cells in vitro. Evaluate CD59 expression in human prostate cancer microarrays.

Aim 4: Evaluate toxicity and efficacy of the lead PAC5 proteins in vivo against PSA producing prostate cancer xenografts.

Body:

Progress over the 2011-2012 reporting period

To generate potential PSA activated PAC5 protein toxins, the C5 cDNA was mutated via site-directed mutagenesis to introduce a PSA recognition sequence in place of the wild type activation sequence. The resulting constructs were transfected into COS-7 cells and the supernatant containing the recombinant protein was collected. Because of the chance the purification tag could alter the conformation and thus hinder the PSA mediated cleavage, we initially generated proteins without a purification tag to first assess PSA cleavage. Once PSA cleavage was confirmed we intend to add the tag.

A series of mutants (Figure 1) were generated using a previously identified 6 amino acid PSA selective cleavage sequence HSSKLQ. This sequence was obtained from a map of PSA cleavage sites within the gel-forming seminal proteins semenogelin I and II, the presumed physiologic substrates for PSA. Additional mutants were generated containing more of the amino acid sequence that flanks the HSSKLQ sequence in semenogelin II. In all, seven mutants were generated.

C5a — C5b (wild type)

- 1 C5a – HSSKLQ// – C5b
- 2 C5a – **VDVREE**HSSKLQ// – C5b
- 3 C5a – VDVREEHSSKLQ//**T** – C5b
- 4 C5a – VDVREEHSSKLQ//**TS** – C5b
- 5 C5a – VDVREEHSSKLQ//**TSLH** – C5b
- 6 C5a – VDVREEHSSKLQ//**TSLHP** – C5b
- 7 C5a – VDVREEHSSKLQ//**TSLHPAH** – C5b

Figure 1: Wild type C5 and a series of mutants incorporating the semenogelin II sequence. Briefly, the sequence connecting C5a and C5b was mutated to resemble the physiological substrate for PSA.

Meanwhile, the mutants were examined in silico for potential structural changes which might predict the likelihood for PSA hydrolysis. Briefly, homology modeling was performed using the SWISS-MODEL[2] homology modeling server via the automated mode using the published crystal structure of C5 as a template (PDB 3CU7)[3]. The homology models suggested adding six more residues of semenogelin II to the left of the PSA recognition sequence and seven more residues

of semenogelin II to the right would result in a α -helix containing the “HSSKLQ” PSA substrate sequence being exposed to the solvent (Figure 2). This mutant was named PAC-7.




Figure 2: Models of (a) wild type C5; (b) Mut-5 protein described by Ogata et al; (c) PAC5-1 mutant with HSSKLQ at the cleavage site; (d) PAC5-7 mutant with additional flanking sequences to create a loop that may be accessible to PSA cleavage. Amino acid at cleavage site depicted in red, N-terminal fragment in green, PAC5-7 insert in yellow.

A plasmid containing PAC-7 was transfected into COS-7 and HEK293T cells and conditioned media containing the recombinant protein was collected. To probe for PSA mediated PAC-7 cleavage, we analyzed PSA treated conditioned media by MALDI-TOF mass spectroscopy. In this experiment, wild type C5 was completely resistant to cleavage by PSA and no release of 11 kDa fragment was observed. In contrast, incubation of the PAC5-7 protein resulted in production of an ~11kDa fragment corresponding to the modified N-terminal portion of the PAC5-7 protein. Based on the MALDI results, high resolution LTQ nanoHPLC/Orbitrap mass spectroscopic analysis was performed to obtain high resolution mass. Sequencing of this mass fragment using the Sequest sequencing algorithm confirmed the correct sequence corresponding to the 80 amino acid N-terminal C5 cleavage product.

To demonstrate selective toxicity in a tissue culture model we first needed to scale up production of PAC5-7. Transient expression resulted in very low yields of protein, so it was decided another expression system would have to be used. A recombinant adenovirus expressing PAC5-7 was made as described by He et al[4]. Briefly, PAC-2 was cloned into pAdTrack-CMV. pAdTrack-CMV-PAC5-7 was transformed into electrocompetent AdEasier cells already harboring pAdEasy-1. Homologous recombination occurs in the AdEasier cells resulting in a ~40kB adenovirus expressing the PAC5-7 DNA. This DNA was purified and transfected into HEK293T cells. Virus production was monitored by GFP expression. After a series of viral amplifications a high titer virus stock was made.

Recombinant PAC5-7 can be expressed by adding viral stock to feeder HEK293 cells. A series of viral transfections were performed to optimize the ratio of recombinant adenovirus to feeder cells. Unfortunately, it was soon realized that because of the replicative nature of the adenovirus we would have to discontinue the use of HEK293s. Viral transfection of the HEK293s not only results in the production of PAC5-7, but also the production of more adenovirus, which in turn lyses the cells before maximum levels of PAC5-7 can be achieved. As an alternative method, Vero cells, isolated from the African green monkey, were chosen to express PAC5-7. Because Vero cells do not harbor the genes required for the adenoviral life cycle, the cells make PAC5-7 but not make more adenovirus and lyse the cells. After 100 hrs, conditioned media from these cells was subject to Ni-NTA batch and column purification and analyzed by Western blot using an anti-penta-His antibody (Figure 4). Acceptable purity was obtained, judged by Western blot.




Figure 4: Western blot of concentrated conditioned media and His-purified PAC5-7 using an anti-penta-His antibody. Concentrated conditioned media show two bands of PAC5-7, one at ~190kDa, and another at 115kDa. It is likely the top band is unprocessed PAC5-7 because of the addition of BME did not reduce the disulfide bond between the alpha and beta chains. However, for an unknown reason primarily the unprocessed PAC-2 flows through the column without binding, while the eluted protein is mostly processed PAC5-7.

PSA mediated PAC-2 cleavage was carried out in PSA buffer and reactions were analyzed by Western blot. We were pleased to see PSA-mediated cleavage of PAC5-7 (Figure 5), but were confused by the pattern of cleavage. We expected the alpha chain (115kDa) to shift down approximately 11kDa representing the liberation of the C5a fragment. Surprisingly, the alpha chain disappeared altogether. Experimental results later confirmed PSA to cleave PAC5-7 multiple times, including near the C-terminus of the α -chain. Cleavage here results in release of a small part of the α -chain along with the His-tag which is lost in the gel front, hence the total disappearance of the band rather than a slight shift when probed with an anti-His antibody.




Figure 5 (A,B): **A** - Results of PSA mediated PAC5-7 cleavage, analyzed by Western blot using an anti-penta-His antibody which recognizes only the C-terminus of the α -chain. PAC5-7 was added to enzymatically active PSA in buffer (first four wells) or buffer alone (second four wells). In absence of PSA, PAC5-7 is stable in buffer. However, when PAC5-7 is treated with PSA both the unprocessed PAC5-7 (190kDa) and processed PAC5-7 (115kDa, alpha chain) show a decrease in levels, suggesting proteolysis is occurring. **B** - Diagram of PAC5-7 structure and on- and off-target PSA cleavage. Experimental results confirm PSA to cleave PAC5-7 off-target multiple times, including near the C-terminus of the α -chain (red arrow). Cleavage here results in release of a small part of the α -chain along with the His-tag which is lost in the gel front, hence the total disappearance of the band rather than a slight shift.




Figure 6. PSA Cleavage of wt C5 after overnight (O/N) incubation.

As a negative control we choose to repeat the experiment with wild type C5 to ensure it was not cleaved by PSA. In a similar manner as PAC5-7 we treated C5 with PSA and looked for the presence of proteolytic products. We were surprised to learn PSA was able to cleave the C5 alpha-chain many times (Figure 6). After much research we learned that while no one has ever described the ability of PSA to cleave any immune proteins, and in particular complement proteins, other proteases had been shown to cleave C3, another protein integral to the complement system. The two proteases shown to cleave C3 were membrane type-1 matrix metalloproteinase and procathepsin-L, both associated with the progression of cancers. We used BLAST [7] to compare sequence similarity between C3 and C5 and learned the two proteins were very similar, with 48% of the residues being “positives”. It is well known that alpha-2-macroglobulin, C3, C4, and C5 all evolved from a common ancestor, so the sequence similarity is to be expected. We hypothesized PSA’s ability to cleave C5 was not unique and that PSA could actually cleave other complement proteins as well. We later confirmed C3 (but not C4) was a substrate of PSA (data not shown). We have followed up these observations to assess the role of PSA in complement regulation. A manuscript describing these results has been submitted for review to the Journal of Immunology and is included as an appendix.

Key Research Accomplishments:

- Putative PSA-activated modified C5 proteins were generated and characterized for PSA cleavage
- Homology modeling of the modified C5 proteins was performed
- A C5 mutant designated “PAC5-7” was created and verified to be PSA-cleavable by mass spectroscopy.
- PAC5-7 displayed an unexpected cleavage pattern when treated with PSA; that is, additional cleavage sites were present. Further studies determined these sites were carried over from wild type C5. It would be a time intensive process to engineer these sites out, with no guarantee of success.
- PSA found to inactivate complement activation through cleavage of C5.
- PSA plays a role in the degradation of complement factor C3.

Reportable Outcomes:

- Graduate student Michael Manning received a pre-doctoral training award from the DOD PCRP (W81XWH-10-PCRP-IDA).
- Graduate student Michael Manning receive his Ph.D. degree (Spring 2012) from the Johns Hopkins University School of Medicine, Department of Pharmacology and Molecular Sciences for this work.
- Manning ML, Williams SA, Jelinek CA, Kostova M, Denmeade SR. Proteolysis of Complement Factors iC3b and C5 by the Serine Protease Prostate-Specific Antigen (PSA) in Prostatic Fluid and Seminal Plasma. Manuscript resubmitted 11/12 to Journal of Immunology
- Manning ML, Kostova M, Williams SA, Denmeade SR. *Trypsin-Like Proteolytic Contamination of Commercially Available PSA Purified from Human Seminal Fluid*. Prostate. 2012;72:1233-8.
- Presentations:

Manning ML, Denmeade SR. (2012) Prostate-specific antigen (PSA) is an immunomodulator. Johns Hopkins Prostate Research Day, Baltimore, MD, February 25, 2012.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) is an immunomodulator. NIH National Graduate Student Research Conference, Bethesda, MD, October 17, 2011.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) is an immunomodulator. Cancer Immunology and Immunotherapy – NCI, Bethesda, MD, September 22, 2011.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) is an immunomodulator. Johns Hopkins Pharmacology Research Retreat, Baltimore, MD, September 10, 2011.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) is an immunomodulator. SKCCC Fellow Research Day, Baltimore, MD, May 17, 2011.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) cleavage and release of activated complement proteins from the cell surface. Johns Hopkins GSA Poster Competition, Baltimore, MD, April 18, 2011.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) cleavage and release of activated complement proteins from the cell surface. Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL, March 22, 2011.

Manning ML, Denmeade SR. (2011) Engineering a Cytolytic Human Protein into a Novel Prostate Cancer Protoxin. Department of Defense Innovative Minds in Prostate Cancer Today Conference, Orlando, FL, March 10, 2011.

Manning ML, Denmeade SR. (2011) Prostate-specific antigen (PSA) cleavage and release of activated complement proteins from the cell surface. Johns Hopkins Prostate Research Day, Baltimore, MD, February 5, 2011.

Conclusion:

Substantial progress was made over the past year to complete the tasks outlined in Aims 1 and 2 of the grant. A series of PSA-activated modified C5 proteins were generated and characterized for PSA activation. While initial studies suggested that wild type C5 was stable in the presence of PSA, further characterization demonstrated that both the wild type and modified C5 proteins were extensively cleaved and degraded by PSA. Thus, while PSA could cleave the engineered cleavage site within the PAC5-7 protein, it also cleaved the protein at multiple off-target sites. This result suggested that the PSA-activated C5 strategy is unlikely to succeed. The significance of the C5 cleavage was further explored in a series of studies that highlighted a potential role for PSA in regulation of complement activity within prostate cancer sites. PSA was able to inactivate complement fixation and MAC formation through degradation of wild type C5. In additional studies, PSA was demonstrated to play a role in degraded complement factor C3 to produce new C3 fragments detectable in human seminal plasma and prostatic fluid. Based on the finding of PSA degradation of C5, we are now exploring whether alternative proteases selectively overexpressed in prostate cancers such as human glandular kallikrein 2, TMPRSS2 and the cancer selective fibroblast activation protein (FAP) can be targeted to activate a modified C5 protein using the same strategy we have outlined for the PSA studies. Over the next year C5 proteins modified to contain previously identified cleavage sites for these proteases will be generated using the same methods we worked out this past year for inserting PSA cleavage sites. These new modified C5 proteins will be evaluated for appropriate cleavage at the engineered site and for selective toxicity against cell lines producing the respective protease.

References:

1. Ogata, R.T. and P.J. Low, *Complement component C5: engineering of a mutant that is specifically cleaved by the C4-specific C1s protease*. J Immunol, 1995. **155**(5): p. 2642-2651.
2. Kopp, J. and T. Schwede, *The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models*. Nucl. Acids Res., 2004. **32**(suppl_1): p. D230-234.
3. Fredslund, F., et al., *Structure of and influence of a tick complement inhibitor on human complement component 5*. Nat Immunol, 2008. **9**(7): p. 753-760.
4. He, T.-C., et al., *A simplified system for generating recombinant adenoviruses*. Proceedings of the National Academy of Sciences of the United States of America, 1998. **95**(5): p. 2509-2514.
5. Rozanov, D.V., et al., *Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice*. Cancer Res., 2006. **66**(12): p. 6258-63.
6. Frade, R., et al., *Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells*. Cancer Res., 1998. **58**(13): p. 2733-6.
7. Altschul, S.F., et al., *Gapped BLAST and PSI-BLAST: a new generation of protein database search programs*. Nucleic Acids Res., **25**: p. 3389-3402.
8. Garin-Chesa, P., et al., *Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers*. Proc Natl Acad Sci 1990;**87**: p.7235-39.
9. Scanlan, M.J., et al., *Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers*. Proc Natl Acad Sci 1994;**91**: p.5657-61.
10. Park J.E., et al., *Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts*. J Biol Chem 1999;**274**: p.36505-12.
11. Aggarwal, S., et al., *Fibroblast Activation Protein Peptide Substrates Identified from Human Collagen I Derived Gelatin Cleavage Sites*. Biochemistry 2008;**47**: p.1076-86.
12. Lebeau, A.M., et al., *Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin*. Mol Cancer Ther. 2009; **8**(5): p.1378-86.

**Proteolysis of Complement Factors iC3b and C5 by the Serine Protease Prostate-Specific Antigen (PSA)
in Prostatic Fluid and Seminal Plasma.**

Michael L. Manning^{*}, Simon A. Williams[†], Christine A. Jelinek^{*},

Maya B. Kostova[‡], Samuel R. Denmeade^{*,†,‡}

**^{*}The Department of Pharmacology and Molecular Sciences, [†]The Brady Urologic Institute and [‡]The
Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine,
Baltimore, MD**

Running Title: PSA cleaves complement factors iC3b and C5

Keywords: complement, protease, PSA, prostate, seminal plasma

**Grant Support: DOD Idea Award W81XWH-10-PCR-IDA to SRD; DOD Predoctoral Fellowship
W81XWH-09-1-0219 to MLM; DOD Post-Doctoral Fellowship to MBK; Prostate SPORE 2P50CA58236
to SRD.**

**Correspondence to: Samuel Denmeade, 1650 Orleans Street, Baltimore, MD 21231; phone- 410.955.8875;
fax- 410.614.8397; email- denmesa@jhmi.edu**

ABSTRACT

Prostate-specific antigen (PSA) is a serine protease that is expressed exclusively by normal and malignant prostate epithelial cells. The continued high-level expression of PSA by the majority of men with both high and low grade prostate cancer (PCa) throughout the course of disease progression, even in the androgen ablated state, suggests PSA may have a role in the pathogenesis of disease. Current experimental and clinical evidence suggests chronic inflammation, irrespective of the cause, may predispose men to PCa. The responsibility of the immune system in immune surveillance and eventually tumor progression is well appreciated yet not completely understood. In this study, we used a mass spectrometric based evaluation of prostatic fluid obtained from diseased prostates after removal by radical prostatectomy to identify potential immunoregulatory proteins. This analysis revealed the presence of immunoglobulins, as well as complement system proteins C3, factor B, and clusterin. Verification of these findings by Western blot confirmed not only the high-level expression of C3 in the prostatic fluid but also the presence of a previously uncharacterized C-terminal C3 cleavage product. Biochemical analysis of this C3 cleavage fragment revealed a putative PSA cleavage site after tyrosine-1348. Purified PSA was able to cleave iC3b and the related complement protein C5. Together these results suggest a previously uncharacterized function of PSA as an immunoregulatory protease that may help to create an environment hospitable to malignancy through proteolysis of the complement system.

INTRODUCTION

Prostate-specific antigen (PSA) is a serine protease that is a unique differentiation product of prostate tissue. PSA is one of the most abundant proteins in the seminal plasma where it is present at mg/ml concentrations. While the exact physiologic role of PSA remains unknown, its major substrates in the seminal plasma are the gel-forming proteins semenogelin (Sg) I and II (1–3). PSA is able to maintain the seminal plasma in a semi-liquid state through cleavage of these gel-forming proteins. PSA is also produced in high amounts by prostate cancer cells. A role for PSA in the pathobiology of prostate cancer has been proposed based on its effect on prostate cancer growth (4) and its ability to cleave several important growth regulatory proteins (5). However, the exact role for PSA in prostate cancer has yet to be clearly defined. PSA is not expressed by any other tissue in the adult human male and leaks out of prostate cancer sites with disrupted tissue architecture. On this basis PSA has utility as a biomarker for prostate cancer. The overwhelming majority of men with prostate cancer, even those with poorly differentiated, high grade disease, continue to express PSA at high levels throughout the course of disease progression.

The word prostate is derived from Greek and literally means “one who stands before” or “protector” (6). While the exact role of the prostate gland is not clear, it is the guardian of the genitourinary tract and prevents foreign materials from entering the reproductive apparatus of the male. In light of this role, the prostate of the aging male exhibits significant chronic inflammation that may lead to the development of prostate cancer (7). However, while the prostate tissue may be pro-inflammatory, the prostatic fluid is not, as evidenced by the fact that men with prostatitis commonly have no or minimal inflammatory cells in the prostatic secretions. Immunoregulation within the prostatic fluid must also be finely balanced. The fluid must have the capability to eliminate foreign bacteria and viruses entering the genitourinary tract through the urethra. It must also shield the sperm from immune destruction within the vaginal tract while at the same time not eliminating cells within the reproductive tract of the female. In this regard, seminal plasma is devoid of complement activity, and actually has a strong anti-complement activity (8–10).

In this study, we used a mass spectrometric based evaluation of prostatic fluid obtained from cancer-containing prostates after removal by radical prostatectomy to identify potential immunoregulatory proteins. This analysis revealed the presence of immunoglobulins, as well as complement system proteins C3, factor B, and clusterin. Verification of these findings by Western blot confirmed not only the high-level expression of C3 but also a previously uncharacterized C-terminal C3 cleavage product. Biochemical analysis of this C-terminal cleavage fragment revealed a putative PSA cleavage site which was confirmed using purified PSA and C3. Further studies revealed PSA to preferentially cleave iC3b, itself a cleavage product resulting from complement activation. We then tested whether this activity had functional consequences on CR3 activation, but could not detect any. Finally we determined that the evolutionarily-related complement protein C5, but not C4, is a substrate of PSA as well. PSA-mediated proteolysis of C5 inhibits complement pathway activity. Together these results suggest a previously unknown function of PSA as an immunoregulatory protease that may help to create an environment hospitable to malignancy through inactivation of the complement system. Finally, these findings suggest PSA may also have immunoregulatory activity in the seminal plasma to aid in normal fertility that may have been co-opted by prostate cancer cells as a means to avoid immune destruction.

MATERIALS AND METHODS

Patient samples and cell lines. Prostatic fluid samples were collected from radical prostatectomy specimens as previously described according to an Institutional Review Board approved protocol (11). Seminal plasma was obtained from discarded clinical samples. The RAW 264.7 macrophage cell line was obtained from ATCC.

Mass spectrometric sample preparation and analysis. Individual prostatic fluid samples were loaded into the wells of a 4-12% Bis-Tris NuPage gel. Following electrophoretic separation the gel was stained with SimplyBlue SafeStain (Invitrogen). Individual gel lanes were excised into 12 similar sized pieces and each piece was placed into a separate microcentrifuge tube. The gel slices were destained with water before being immersed into 500 μ l of 100 mM ammonium bicarbonate. In-gel tryptic digestion was performed on all gel slices (1:20 ratio trypsin enzyme:substrate) for 18 hours at 37°C. Mass spectrometric analysis and subsequent protein identifications were performed as previously described (4).

Western blot. Prostatic fluid samples stored at -80°C were thawed, centrifuged, and protein concentrations in the supernatant were determined by the BCA method. Proteins (5 μ g) were separated by SDS-PAGE and then transferred to PVDF membrane (Bio-Rad). Membranes were blocked with 4% nonfat milk in TBS-Tween 0.1%. Primary and secondary antibodies were prepared in the same diluent. The membrane was probed with monoclonal anti-human-C3b- α (1:10,000; clone H206) from Millipore and ECL-anti-mouse IgG (1:8000) from GE Healthcare. The membrane was incubated with SuperSignal West Pico Substrate (Pierce) then exposed to X-ray film.

Immunoaffinity purification. Polyclonal anti-C3 (Complement Technology) was covalently linked to AminoLink Coupling Resin (Pierce) by following the manufacturer's instructions. Briefly, 16.5 mg antibody was diluted into 2 mL coupling buffer before adding 40 μ L sodium cyanoborohydrate. This mixture was added to 2 mL of resin and incubated for 5 hours under gentle agitation. The column was washed then remaining active sites were blocked before additional washing. Four prostatic fluid samples were pooled then diluted to 1.5 mL in TBS. Samples were added to the prepared column and binding occurred for 1 hour. The column was

washed then elution buffer was added and 1 mL fractions were collected. Fractions containing relevant protein were concentrated using an Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore).

Edman degradation. Concentrated immunopurified prostatic fluid was separated on a 4-15% gel and transferred to a PVDF membrane. The membrane was cut in half where a small amount of immunopurified sample was probed with the anti-human-C3b- α antibody as described above. The remaining membrane was incubated with Coomassie stain before a brief destain. The X-ray film was overlaid onto the Coomassie-stained membrane to identify the correct band which was then excised and sent to the Johns Hopkins Synthesis and Sequencing Facility for Edman degradation. The first seven N-terminal amino acids were determined with a Perkin-Elmer/Applied Biosystems Procise Protein Sequencing System.

Coincubation of C3/C3b/iC3b and PSA. Purified human C3, C3b, and iC3b (Complement Technology) were incubated with enzymatically active PSA (AbD Serotec) in the presence of 10 μ M aprotinin (Sigma). PSA inhibitor (1 μ M) was added to control reactions. Reactions took place in PSA buffer (50 mM Tris, 100 mM NaCl, pH = 7.5) overnight at 37°C. Reactions were stopped by addition of sample loading buffer. Proteins were separated by SDS-PAGE and transferred to PVDF membrane as described above. Membranes were stained with Coomassie blue, briefly destained, then digitally imaged. The band at ~37 kDa was excised and sent for Edman degradation as described above.

Determination of cofactor activity. Purified human C3b was incubated with enzymatically active PSA and an increasing amount of factor H (Quidel). Reactions took place in PSA buffer overnight at 37°C. Reactions were stopped by addition of sample loading buffer. Proteins were separated by SDS-PAGE and transferred to PVDF membrane as described above.

C3b/iC3b deposition assay. Sheep erythrocytes (E_S) were opsonized with C3b as described (12). iC3b opsonized sheep erythrocytes were prepared by incubating antibody sensitized sheep erythrocytes (E_A) with C5-depleted serum. Approximately 2 million E_A (Complement Technology) were mixed with 10 μ L of normal human serum stripped of C5 by immunoaffinity chromatography (C5 (-) NHS) in triplicate. After 20 minutes at 37°C erythrocytes were washed twice with PBS. E_S and E_A were resuspended in PSA or BSA (125 μ g/mL) in the presence of aprotinin (10 μ M) then incubated at 37°C for 2 hours on a rotisserie mixer. Cells were washed

once with PBS then resuspended in a 10 µg/mL solution of anti-human-C3b-α (clone H206) and incubated for 1 hour on ice. Cells were washed once with PBS then resuspended in a 10 µg/mL solution of anti-mouse IgG Alexa Fluor 488 and incubated for 30 minutes on ice in the dark. Cells were washed with PBS then fixed with formalin. Levels of C3b-α were measured by a BD FACSCalibur at the Sidney Kimmel Comprehensive Cancer Center Flow Cytometry Core Facility.

CR3-mediated phagocytosis of E_A-iC3b. Assessment of complement-mediated phagocytosis was performed as described (13, 14). E_A-iC3b were prepared as described above. E_A-iC3b were incubated with enzymatically active PSA or BSA in PSA buffer overnight at 37°C. RAW 264.7 cells were propagated in DMEM supplemented with 10% FBS in a humidified atmosphere of 5% CO₂ at 37°C. The cells were seeded on poly-llysine coated 96-well plates such that they were 90% confluent on the day of experimentation. RAW 264.7 cells were stimulated with 125 ng/µL phorbol 12-myristate 13-acetate (PMA, Promega) for 10 minutes at 37°C. E_A-iC3b pretreated with PSA or BSA were added to the stimulated RAW 264.7 cells and phagocytosis proceeded for 75 minutes at 37°C. Phagocytosis was quantified colorimetrically by the conversion of 2,7-diaminofluorene by hemoglobin into a product that absorbs at 620 nm. The RAW 264.7 cells were washed twice in PBS. Erythrocytes that had bound but not been internalized were lysed by a brief incubation in 0.2% NaCl. The RAW 264.7 cells were again washed twice in PBS before being lysed with 50 µL of 6M urea in 0.2M Tris-HCl pH=7.4. The cell lysates were mixed with 75 µL of working solution (10 volumes 0.2M Tris-HCl pH=7.4, 1 volume 2,7-diaminofluorene stock, and 0.02 volumes 30% hydrogen peroxide). Absorbance at 620 nm was monitored with a plate reader.

Coincubation of C4/C5 and PSA. Purified human C4 and C5 (Complement Technology) were incubated with enzymatically active PSA in the presence of 10 µM aprotinin in PSA buffer. After overnight incubation at 37°C the reaction products were separated by SDS-PAGE and stained with SimplyBlue SafeStain.

C5 supplementation of C5 (-) NHS. Purified human C5 was mixed with enzymatically active PSA or BSA and incubated overnight at 37°C. The next day 50 µL of E_A were supplemented with 2 µL of C5 (-) NHS. The C5 pretreated with PSA or BSA was added to the erythrocytes and incubated at 37°C for 20 minutes. Reactions

were centrifuged at 1000 x g and the supernatants were collected. The absorbance of the supernatant at 415nm was recorded.

Comparison of C5 levels in serum, prostatic fluid, and seminal plasma. A Western blot was performed as described above. The membrane was probed with polyclonal anti-human-C5 (1:2,000) from Complement Technology and donkey anti-goat IgG-HRP (1:20,000) from Santa Cruz Biotechnology.

Addition of C5 to fresh seminal plasma. Purified human C5 in PSA buffer was incubated with fresh seminal plasma for 2 hours at 37°C. PSA inhibitor (10 μ M) was added to control reactions. Reactions were stopped by addition of sample loading buffer. A Western blot was performed as described above. The membrane was probed with polyclonal anti-human-C5 (1:2,000) and donkey anti-goat IgG-HRP (1:20,000).

RESULTS

Mass spectrometric based identification of 95 proteins in prostatic fluid. All protein species identified from the prostatic fluid of each of 4 patients were introduced into the proteomic platform Protein Center (Thermo Fisher Scientific) as individual patient proteome files using the methodology outlined by Williams et al (4). A comparative analysis was performed to determine which proteins had been identified in all analyzed patient samples (Figure 1A and Supplemental Table I). The 95 proteins common to all 4 patients were introduced as an independent data set. Using the seminal plasma proteome published by Bartosz Pilch and Matthias Mann (15) as a reference database, the subset of common experimentally identified proteins was compared to the reference database. Of the 95 proteins included in the experimental data set, 58 had previously been identified in seminal plasma (Figure 1B). Both our dataset and the dataset of Pilch and Mann included proteins known to be expressed by the prostate at high levels such as PSA and prostatic acid phosphatase; inclusion of these proteins served as internal validation. Complement system proteins C3, factor B and clusterin were detected in all 4 patient samples. These three proteins were also present in the reference database. Additional complement proteins present in the reference database but not in our dataset included C1, C2, C4, C9, and complement factor I.

C3 and a previously uncharacterized C3 fragment are present in diseased prostatic fluid and normal seminal plasma. To confirm the results from our proteomic study, we analyzed eight additional prostatic fluid samples from men with prostate cancer by Western blot to confirm the presence of C3. The antibody for this analysis, monoclonal anti-human-C3b- α (clone H206), is directed towards an epitope present on the α -chain of the C3 protein. While the exact epitope recognized by this antibody is not known, it is able to detect both C3b and C3c consistent with detection of an epitope towards the C-terminus of the C3 α -chain (16). C3 was detected in all eight prostatic fluid samples and in the seminal plasma of a healthy male (Figure 1C). While equal amounts of protein were loaded for each sample varying levels of C3 were detected by Western blot. Six of the eight prostatic fluid samples also tested positive for a C3 fragment of approximately 105 kDa, which most likely

represented C3b, which is evidentiary of complement activation. All eight prostatic fluid samples and the seminal plasma from a healthy donor also tested positive for a 37 kDa fragment using the anti-C3b- α antibody. This 37 kDa fragment was not detected in the serum of healthy individuals or in the serum of patients with prostate cancer (data not shown). Of the previously described C3 cleavage fragments this 37 kDa fragment appears to be closest in size to C3c α -chain fragment 2.

Characterization of the novel 37 kDa C3 fragment. C3 is a well characterized protein whose activation and degradation is tightly regulated. Following conversion to C3b by the C3 convertase complex, C3b is subsequently inactivated by the proteolytic activity of factor I in the presence of co-factor molecules factor H, CR1, or CD46/membrane co-factor protein (MCP). Factor I cleavage generates multiple previously characterized cleavage fragments that include C3c, C3dg and C3f (17) (Figure 2). To better characterize this putative C3 fragment, immunoaffinity purification was utilized to purify the 37 kDa fragment from prostatic fluid for further characterization. Purification was achieved using a polyclonal C3 antibody. Because prostatic fluid sample volume was limited, four samples were pooled prior to purification. Seven cycles of Edman degradation on the purified pooled prostatic fluid samples revealed the amino acid sequence of the N-terminus of the 37 kDa fragment to be “HAKAKDQ”. Comparison to the C3 reference sequence indicates the 37 kDa fragment is indeed a previously undescribed C3 fragment that maps to the 36.5 kDa C-terminal portion of the C3 α -chain (Figure 2). This 37 kDa fragment is detectable under reducing conditions by Western blot due to its release from the N-terminal portion of the C3 α -chain following reduction of the disulfide bond. Further inspection of the sequence flanking the cleavage site revealed that the new N-terminus was created by a chymotrypsin-like protease with cleavage after tyrosine-1348 in the C3 protein. In contrast, all other previously described C3 cleavage fragments are produced following cleavage by trypsin-like proteases. Furthermore, cleavage at tyrosine-1348 to generate the 37 kDa fragment, like every other previously described C3 fragment, is the result of cleavage within the C3 α -chain. C3 β -chain cleavage fragments have not been described.

PSA can cleave C3 and generate the 37 kDa fragment in vitro. PSA is the major chymotrypsin-like serine protease in the seminal plasma and prostatic fluid. Therefore, we hypothesized that PSA was cleaving C3 based on sequence similarity between known PSA substrates and the cleavage sequence N-terminal to the tyrosine-

1348 within C3, “TLSVVTMY//HAKAKDQ” (Figure 2). To test this we incubated purified human C3 with purified enzymatically active PSA. Addition of a potent and specific PSA inhibitor (18) served as a negative control. Reducing gel electrophoresis revealed no significant cleavage of the C3 α -chain (Figure 3A). This led us to hypothesize tyrosine-1348 was part of a cryptic site exposed after proteolytic activation of C3 into C3b or iC3b. To test this we incubated purified human C3b and iC3b with purified enzymatically active PSA, again using a PSA inhibitor as a negative control. Reducing gel electrophoresis revealed degradation of both fragments of the iC3b α -chain, however no effect was observed with C3b (Figure 3A). Cleavage of iC3b resulted in a fragment at a similar molecular weight as that observed following similar analysis of the prostatic fluid samples. To confirm this cleavage product was the same proteolytic fragment detected in the prostatic fluid we excised and sequenced the 37 kDa band by Edman degradation. The N-terminus of the PSA generated fragment was confirmed to be “HAKAKDQ” consistent with cleavage after tyrosine-1348.

Factor H does not have cofactor activity to facilitate PSA-mediated cleavage of C3b. Factor I is unable to cleave C3b in the absence of the cofactor Factor H. Therefore, we hypothesized that factor H may also have cofactor activity for PSA enabling it to cleave C3b. To test this we repeated our C3b proteolysis assay with PSA in the presence of complement factor H (Figure 3B). Results show factor H does not impart any cofactor activity on PSA to mediate cleavage of C3b.

PSA cleaves iC3b, but not C3b, deposited on the surface of sheep erythrocytes. The next experiments were performed to determine whether PSA could cleave C3b or iC3b in a more relevant cellular context. Sheep erythrocytes (E_S) were opsonized with C3b using purified C3 and alternative pathway enzymes factor B and factor D in the absence of factor I and H to prevent cleavage of C3b to iC3b. Antibody-sensitized sheep erythrocytes (E_A) were opsonized with iC3b by brief incubation with C5-depleted normal human serum. The addition of C5-depleted serum ensures the complement activation pathway only proceeds through deposition of C3b on the cell membrane and prevents the formation of the membrane attack complex and subsequent cell lysis. Factors I and H present in the C5-depleted serum converts C3b into iC3b. E_S -C3b and E_A -iC3b were incubated with enzymatically active PSA at 37°C. The erythrocytes were collected and labeled with monoclonal anti-human-C3b- α (clone H206) and analyzed by flow cytometry. Analysis revealed a decrease in C3b- α

antibody signal when E_A-iC3b were treated with 125 µg/mL PSA (approximately a 10-fold lower level of PSA than that observed in the prostatic fluid (19)) compared to the signal observed when cells were treated with the same concentration of BSA (Figure 4A). Treatment of E_S-C3b with PSA did not result in a decrease of the C3b-α antibody signal (Figure 4B). To determine whether PSA was releasing the 37 kDa iC3b fragment into the supernatant we collected and tested it for the presence of C3 fragments by Western blot. Two C3 fragments, one at 37 kDa and another at 39 kDa, were detected consistent with a combination of factor I and PSA cleavage (Figure 4C).

PSA-mediated cleavage of E_A-iC3b does not alter complement-dependent phagocytosis. After conversion of C3b to its inactivated form, iC3b can no longer bind factor B and act as a C3 convertase. However iC3b and its degradation product C3dg are active molecules which trigger specialized immune responses by interacting with complement receptors on leukocytes (20). Complement-dependent phagocytosis is an important mechanism of the host defense system and is primarily mediated by complement receptor CR3, and to a lesser extent CR1 and CR4. CR3 is expressed on many immune cells including macrophages, monocytes, and neutrophils. C3b does not interact with CR3, and iC3b is predicted to interact with CR3 through binding sites which become exposed upon unfolding of the CUB domain after cleavage of the C3b α-chain (21). We hypothesized that PSA's ability to cleave iC3b between the CUB and MG8 domain on the α-chain might interfere with CR3 binding. To test this we used an established protocol to measure complement-dependent phagocytosis (14). In this assay the CR3⁺ RAW 264.7 macrophage cell line internalizes iC3b opsonized sheep erythrocytes. PSA treated E_A-iC3b were prepared as usual and were added to pre-stimulated RAW cells at a 20:1 ratio. Phagocytosis was stopped and bound cells that had not internalized were lysed by addition of a hypotonic solution. A sensitive colorimetric assay that relies on the pseudoperoxidase activity of hemoglobin was used to evaluate the phagocytic efficiency (13). Cells were lysed and hemoglobin was released from internalized E_A-iC3b. The relative internalization can be measured by the pseudoperoxidase activity of hemoglobin which converts 2,7-diaminofluorene into fluorene blue which can be measured spectrophotometrically. This sensitive method of detection did not demonstrate any difference in the degree of phagocytosis between PSA-treated and control E_A-iC3b (Figure 5).

PSA also cleaves the homologous C5 protein. The complement system is a collection of over 30 different proteins. Three key components (C3, C4, and C5) are thought to have evolved from a common ancestor, and all share a similar molecular weight and chain structure (22). Because of the similarities between the three proteins we were curious if C3 was uniquely cleaved by PSA or if all were substrates of PSA. We treated C4 and C5 with enzymatically active PSA and looked for cleavage products by electrophoresis. We could not detect any significant proteolysis of the C4 α - or β -chains (Figure 6A). The α -chain of C5 exhibited significant proteolytic degradation, while the β -chain was left intact (Figure 6B), similar to what we observed with C3.

PSA-mediated cleavage of C5 has functional consequences. We were curious if PSA-mediated cleavage of C5 had functional consequences on the integrity of the complement cascade. To test this we used E_A to assay total complement hemolytic activity. C5 was incubated with PSA overnight. The following day we supplemented C5-depleted normal human serum with PSA-treated C5 or control C5, and added it to E_A . We observed significantly less complement activity in the sample supplemented with PSA-treated C5 compared to control C5, indicating that PSA-mediated proteolysis of C5 negatively regulates the complement pathway (Figure 6C).

Proteolysis of C5 in the seminal plasma can be abrogated by a PSA inhibitor. Seminal plasma is a rich source of proteins, including proteins of the complement system (15). However, unlike serum, this fluid is not a source of fully functional complement, likely due to both the presence of complement inhibitory proteins and the absence of certain complement factors. Notably missing in the seminal plasma is C5 (Figure 7A). We were curious if the lack of C5 in seminal plasma might be due in part to PSA proteolytic activity. To answer this question we supplemented seminal fluid with purified human C5 in the presence or absence of a PSA inhibitor. We then determined C5 levels by Western blot with a polyclonal antibody. In the absence of a PSA inhibitor seminal plasma was able to degrade the α -chain of C5, leaving the β -chain intact (Figure 7B).

DISCUSSION

Complement is regarded as one of the first lines of immunological defense, defending the host from foreign invaders by one of three pathways of activation known as the classical pathway, alternative pathway, and lectin pathway (23). Complement factor C3 plays a central role in the complement cascade and supports the activation of all three pathways. Human C3 is the most abundant complement protein in the serum and, based on our proteomic studies of the prostatic fluid, is also one of the most abundant proteins in the seminal plasma. C3 is highly regulated both prior to and following activation by C3 convertases. Cleavage by C3 convertases releases the anaphylatoxin C3a and generates C3b. Once formed, C3b rapidly attaches via covalent bond formation to various acceptors on the surface of bacteria and host cells. Since C3b does not have the ability to discriminate between self and non-self, it has the potential to damage host cells. Therefore, membrane bound C3b activity must be regulated by other complement proteins. In this regard C3b expresses multiple binding sites for other complement components that either amplify its convertase activity (factor B and properdin in the presence of factor D) or inactivate its activity (proteolysis by factor I in the presence of factor H, CR1 or CD46). C3b's factor I mediated degradation product, iC3b, has an equally interesting biology. iC3b interacts with CR2, CR3, and CR4, the first of which plays a role in enhancing B-cell immunity. iC3b's other receptor binding partners, CR3 and CR4, play a role in clearance of pathogens by phagocytosis. In this study we provide initial evidence that human PSA, via its chymotrypsin-like serine protease activity, can modulate the complement system through degradation of iC3b to produce new C3 degradation fragments and through degradation of the complement protein C5, thereby inactivating the complement cascade.

In this study, PSA was shown to cleave iC3b and was unable to cleave C3 or C3b. C3 is known to undergo a significant conformational change upon activation into C3b and then again following deactivation into iC3b by sequential proteolysis (21, 24–27). High-resolution crystal structures exist for both C3 and C3b documenting these conformational changes. These crystal structures detect a conformational change of up to 95Å and the exposure of cryptic binding sites. Examination of the crystal structures of C3 and C3b (PDB ID 2A73 and 2I07, respectively) reveal that the PSA cleavage site at tyrosine-1348 is part of a β -strand facing the

interior of the protein, making it an inaccessible substrate of PSA. Unfortunately, we have a limited understanding of the structure of iC3b. The conversion from C3b to iC3b likely results in significant shifts and the generation of cryptic binding sites much like the earlier conversion from C3 to C3b. iC3b, but not C3b, interacts with CR2, CR3, and CR4, so these sites must be hidden in C3b but made accessible upon conversion to iC3b. Low resolution 3D-electron microscopy analysis of iC3b confirms a significant conformational change upon conversion from C3b to iC3b, but cannot provide atomic resolution (26). Our results indicate only iC3b to be a substrate of PSA, suggesting conversion into iC3b makes tyrosine-1348 accessible to the solvent and thus PSA-mediated proteolysis.

To confirm this proteolytic activity could be duplicated in a more relevant cellular context we repeated the assay with C3b and iC3b covalently attached to the surface of sheep erythrocytes (E_S -iC3b and E_A -iC3b, respectively) and analyzed it by flow cytometry. Following C3 activation, C3b becomes attached to cell membranes due to formation of a covalent bond between the C3b protein and the cell surface. This bond is formed when exposed hydroxyl and amine groups on cell surface proteins and carbohydrates interact with the reactive thioester bond within the C3b protein. C3b is subject to factor I proteolysis resulting in iC3b, itself an important protein which uniquely interacts with CR2, CR3, and CR4. We treated both E_A -iC3b and E_S -C3b with PSA, but observed a decrease in antibody signal only with E_A -iC3b, consistent with removal of part or all of iC3b from the erythrocyte surface. After PSA treatment the 37 kDa iC3b fragment could be detected in the supernatant. PSA-mediated cleavage of iC3b after tyrosine-1348 alone would not liberate the 37 kDa fragment from the surface of the cell due to disulfide bonds linking the iC3b α -chain fragments 1 and 2. Electrophoretic analysis indicates additional PSA-mediated cleavage of iC3b (Figure 3A), including cleavage of the α -chain fragment 1, which would release the 37 kDa fragment from surface of the erythrocyte. Unfortunately cleavage of the α -chain fragment 1 appears to be nearly complete, making characterization of these cleavage fragments technically challenging. In the absence of PSA the α -chain fragment 2 (39.5 kDa) can also be detected in the supernatant (Figure 4C), indicating additional proteolysis is occurring, perhaps by factor I and the appropriate cofactor.

Complement-dependent phagocytosis is an important mechanism of the host defense system and is primarily mediated by complement receptor CR3, and to a lesser extent CR1 and CR4. Many leukocytes express CR3, including professional phagocytes such as macrophages, monocytes, and neutrophils. C3b does not interact with CR3, and iC3b is predicted to interact with CR3 through binding sites which become exposed upon unfolding of the CUB domain after cleavage of the C3b α -chain. We hypothesized that the significance of PSA's ability to cleave iC3b between the CUB and MG8 domain on the α -chain might be that it results in interference with CR3 binding and subsequent phagocytosis. However, we could not detect any difference in phagocytosis between PSA treated and control E_A-iC3b. Thus, PSA-mediated proteolysis of purified iC3b may have other effects. In particular, we are currently exploring whether the 37 kDa C3 fragment generated by the combination of factor I and PSA cleavage has unique effects within the immune system.

C3, C4, and C5 are key components of the complement system and are similar in size (~200 kDa) and subunit structure. These homologous complement factors belong to the same gene family as the serum proteinase inhibitor α -2-macroglobulin and are the result of gene duplication (22). Interestingly, α -2-macroglobulin is the primary inhibitor of PSA in the serum. Owing to the similarities between this group of proteins we were curious if C3 was uniquely cleaved by PSA or if all family members were substrates of PSA. C5, but not C4, was degraded by PSA in a manner similar to that of C3, although the cleavage products were too numerous for further analysis. PSA's lack of proteolytic activity towards C4 confirms PSA is not a promiscuous protease, and the activity towards C3 and C5 is likely specific. Similar to C3, cleavage of C5 was limited to the α -chain, leaving the β -chain entirely intact. In this study, C5 was readily degraded and inactivated upon addition to seminal plasma. This degradation could be blocked through the addition of a specific PSA inhibitor. These results suggest that PSA present in the seminal/prostatic fluid has the ability to degrade C5 present in the male reproductive tract. In addition, it is possible that PSA may play a further immunosuppressive role by cleaving and inactivating C5 that is known to be present in the female reproductive tract, thus protecting spermatozoa from complement-mediated injury. The continued high-level expression of PSA by localized and metastatic prostate cancer cells, even after progression into disease castration resistant state, suggests that PSA might have a role in the initiation and/or progression of prostate cancer (5). Previous

studies demonstrated that PSA may modulate a variety of cytokines and growth factors. PSA was first shown to cleave insulin-like growth factor binding proteins (IGFBP) resulting in the release of reactive insulin growth factor 1 (IGF-1) (28) and to release TGF β from the small latent complex (29). PSA can also cleave parathyroid hormone-related protein (PTHrP) to produce a fragment that through recruitment of other factors may promote an osteoblastic phenotype (30). However, in each of these studies PSA cleavage was only demonstrated in biochemical assays using purified proteins. Whether any of these proteins are relevant PSA substrates in vivo is not known. In contrast, in this current study we have been able to demonstrate in an in vivo context PSA's ability to proteolyze complement proteins in patient prostatic fluid samples. In this context, further study is necessary to understand the significance of PSA's ability to cleave iC3b and C5 as it relates to the avoidance or inhibition of native immune suppression of prostate cancer growth and progression. These findings may also have bearing on the potential development of antibody and cell-based therapeutics for prostate cancer. Finally, it is necessary to determine if these new PSA-induced C3 fragments can be detected in serum and have potential utility as biomarkers for prostate cancer.

ACKNOWLEDGEMENTS: The authors would like to acknowledge the support of the Middle Atlantic Mass Spectrometry Laboratory at Johns Hopkins. The authors wish to thank Lizamma Antony for excellent technical support. We would like to thank Nenoo Rawal and Michael Pangburn at Complement Technology for thoughtful discussions.

REFERENCES

1. Watt, K. W., P. J. Lee, T. M'Timkulu, W. P. Chan, and R. Loor. 1986. Human prostate-specific antigen: structural and functional similarity with serine proteases. *Proceedings of the National Academy of Sciences* 83: 3166–3170.
2. Lilja, H. 1985. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. *J Clin Invest* 76: 1899–1903.
3. Lilja, H., P. A. Abrahamsson, and A. Lundwall. 1989. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. *Journal of Biological Chemistry* 264: 1894–1900.
4. Williams, S. A., C. A. Jelinek, I. Litvinov, R. J. Cotter, J. T. Isaacs, and S. R. Denmeade. 2011. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. *Prostate* 71: 1595–1607.
5. Williams, S. A., P. Singh, J. T. Isaacs, and S. R. Denmeade. 2007. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? *Prostate* 67: 312–329.
6. Josef Marx, F., and A. Karenberg. 2009. History of the Term Prostate. *Prostate* 69: 208–213.
7. De Marzo, A. M., E. A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, C. G. Drake, Y. Nakai, W. B. Isaacs, and W. G. Nelson. 2007. Inflammation in prostate carcinogenesis. *Nat Rev Cancer* 7: 256–269.
8. Brooks, G. F., C. J. Lammel, B. H. Petersen, and D. P. Stites. 1981. Human seminal plasma inhibition of antibody complement-mediated killing and opsonization of *Neisseria gonorrhoeae* and other gram-negative organisms. *Journal of Clinical Investigation* 67: 1523–1531.
9. Petersen, B., C. Lammel, D. Stites, and G. F. Brooks. 1980. Human seminal plasma inhibition of complement. *J Lab Clin Med* 96: 582–91.

10. Tarter, T., and N. Alexander. 1984. Complement-inhibiting activity of seminal plasma. *Am J Reprod Immunol.* 6: 28–32.
11. Fujita, K., C. M. Ewing, L. J. Sokoll, D. J. Elliott, M. Cunningham, A. M. De Marzo, W. B. Isaacs, and C. P. Pavlovich. 2008. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. *Prostate* 68: 872–882.
12. Rawal, N., and M. Pangburn. 2001. Formation of high-affinity C5 convertases of the alternative pathway of complement. *J. Immunol.* 166: 2635–2642.
13. Montaña, R. F., and S. L. Morrison. 1999. A colorimetric-enzymatic microassay for the quantitation of antibody-dependent complement activation. *J. Immunol. Methods* 222: 73–82.
14. Chow, C.-W., G. P. Downey, and S. Grinstein. 2004. Measurements of phagocytosis and phagosomal maturation. *Curr Protoc Cell Biol* Chapter 15: Unit 15.7.
15. Pilch, B., and M. Mann. 2006. Large-scale and high-confidence proteomic analysis of human seminal plasma. *Genome Biology* 7: R40.
16. Burger, R., A. Bader, M. Kirschfink, U. Rother, L. Schrod, I. Wörner, and G. Zilow. 1987. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. *Clin. Exp. Immunol.* 68: 703–711.
17. Sahu, A., and J. D. Lambris. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. *Immunological Reviews* 180: 35–48.
18. LeBeau, A. M., P. Singh, J. T. Isaacs, and S. R. Denmeade. 2008. Potent and Selective Peptidyl Boronic Acid Inhibitors of the Serine Protease Prostate-Specific Antigen. *Chemistry & Biology* 15: 665–674.
19. Denmeade, S. R., L. J. Sokoll, D. W. Chan, S. R. Khan, and J. T. Isaacs. 2001. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. *Prostate* 48: 1–6.

20. Van Lookeren Campagne, M., C. Wiesmann, and E. J. Brown. 2007. Macrophage complement receptors and pathogen clearance. *Cell. Microbiol.* 9: 2095–2102.
21. Nishida, N., T. Walz, and T. A. Springer. 2006. Structural transitions of complement component C3 and its activation products. *Proceedings of the National Academy of Sciences* 103: 19737–19742.
22. Hughes, A. L. 1994. Phylogeny of the C3/C4/C5 complement-component gene family indicates that C5 diverged first. *Mol. Biol. Evol.* 11: 417–425.
23. Walport, M. J. 2001. Complement. *New England Journal of Medicine* 344: 1058–1066.
24. Janssen, B. J. C., A. Christodoulidou, A. McCarthy, J. D. Lambris, and P. Gros. 2006. Structure of C3b reveals conformational changes that underlie complement activity. *Nature* 444: 213–216.
25. Wiesmann, C., K. J. Katschke, J. Yin, K. Y. Helmy, M. Steffek, W. J. Fairbrother, S. A. McCallum, L. Embuscado, L. DeForge, P. E. Hass, and M. van Lookeren Campagne. 2006. Structure of C3b in complex with CR1g gives insights into regulation of complement activation. *Nature* 444: 217–220.
26. Alcorlo, M., R. Martínez-Barricarte, F. J. Fernández, C. Rodríguez-Gallego, A. Round, M. C. Vega, C. L. Harris, S. R. de Cordoba, and O. Llorca. 2011. Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy. *Proc. Natl. Acad. Sci. U.S.A.* 108: 13236–13240.
27. Janssen, B. J. C., E. G. Huizinga, H. C. A. Raaijmakers, A. Roos, M. R. Daha, K. Nilsson-Ekdahl, B. Nilsson, and P. Gros. 2005. Structures of complement component C3 provide insights into the function and evolution of immunity. *Nature* 437: 505–511.
28. Cohen, P., H. C. Graves, D. M. Peehl, M. Kamarei, L. C. Giudice, and R. G. Rosenfeld. 1992. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. *Journal of Clinical Endocrinology & Metabolism* 75: 1046–1053.

29. Dallas, S. L., S. Zhao, S. D. Cramer, Z. Chen, D. M. Peehl, and L. F. Bonewald. 2005. Preferential production of latent transforming growth factor β -2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. *J. Cell. Physiol.* 202: 361–370.
30. Cramer, S. D., Z. Chen, and D. M. Peehl. 1996. Prostate Specific Antigen Cleaves Parathyroid Hormone-Related Protein in the PTH-like Domain: Inactivation of PTHrP-Stimulated cAMP Accumulation in Mouse Osteoblasts. *The Journal of Urology* 156: 526–531.

Figure legends

Figure 1 – Proteomic analysis of prostatic fluid samples from radical prostatectomy specimens of men with prostate cancer. (A) Examples of the 95 proteins identified in each of four prostatic fluid samples. Y-axis indicates number of peptide “hits” for each protein from mass spectrometric analysis. (B) The prostatic fluid experimental dataset has considerable overlap with the previously described seminal plasma reference database. A Venn diagram was constructed showing overlap between protein species identified in our screen of prostatic fluid samples and the seminal plasma reference proteome of Pilch and Mann (12). Protein species found in our screen must have been identified in all four prostatic fluid samples to be included in the comparison. (C) Patient prostatic fluid and normal seminal plasma contains native C3 and a C3 fragment at approximately 37 kDa. Western blot of eight random prostatic fluid samples, purified human C3, and the seminal plasma of a healthy donor were probed for the presence of C3 with a monoclonal anti-human-C3b- α (clone H206) antibody.

Figure 2 - Schematic of complement C3 activation and degradation. After activation by the convertase, C3 is subject to normal degradation involving sequential factor I cleavage with factor H cofactor activity. iC3b is then subject to PSA cleavage after tyrosine-1348 and potentially other uncharacterized sites. PSA cleavage results in the production of a new 37 kDa fragment. The black square indicates the thioester site within C3.

Figure 3 – (A) PSA preferentially cleaves iC3b. Purified human C3, C3b and iC3b were incubated with enzymatically active PSA in the presence of 10 μ M aprotinin. PSA inhibitor (1 μ M) was added to control reactions. Coomassie staining of a gel run under reducing conditions revealed a cleavage product at approximately 37 kDa that was generated in the absence of PSA inhibitor. (B) Factor H does not have cofactor activity for PSA-mediated cleavage of C3b. Purified human C3b was incubated with enzymatically active PSA and an increasing amount of factor H. Proteins were separated by SDS-PAGE and transferred to PVDF membrane before staining with coomassie blue.

Figure 4 – PSA is able to remove the 37 kDa C3 fragment from the surface of sheep erythrocytes opsonized with iC3b, but not C3b. (A) Antibody-sensitized sheep erythrocytes (EA) were coated with iC3b using C5-depleted serum before treatment with equal amounts of PSA or BSA. (B) Sheep erythrocytes (ES) were coated

with C3b using purified alternative pathway proteins and then treated with equal amounts of PSA or BSA. Flow cytometric analysis was performed to assess the amount of iC3b or C3b on the surface using an anti-C3 antibody. Because the cell population was homogenous all cells were included in the gate. (C) The supernatant was isolated from PSA-treated iC3b-opsonized erythrocytes and probed for presence of the 37 kDa fragment and other C3 fragments under reducing conditions by Western blot with the H206 antibody.

Figure 5 - PSA-mediated cleavage of iC3b does not affect CR3-dependent phagocytosis. Sheep erythrocytes opsonized with iC3b were treated with PSA (100 μ g/mL) or an equal amount of BSA overnight. RAW 264.7 cells were stimulated with 125 nM phorbol 12-myristate 13-acetate (PMA) for 10 minutes, after which erythrocytes were added (approximately 20:1). The erythrocytes were phagocytized for 75 minutes. Erythrocytes bound but not internalized were lysed, and the number of erythrocytes phagocytosed were quantified by the colorimetric conversion of 2,7-diaminofluorene to fluorene blue (OD620) by the pseudoperoxidase activity of hemoglobin.

Figure 6 – (A) PSA does not cleave C4. (B) PSA cleaves the C5 α -chain, leaving the β -chain intact. Purified human C4 and C5 was incubated with enzymatically active PSA in the presence of 10 μ M aprotinin. Coomassie staining of a gel run under reducing conditions revealed proteolysis of the C5 α -chain. (C) PSA-mediated cleavage of C5 is inhibitory. C5-depleted normal human serum was supplemented with C5 that had been incubated with PSA or BSA overnight. This serum was added to EA. Complement activity was quantified by absorbance of the supernatant at 415nm following hemolysis.

Figure 7 – (A) C5 is not present in diseased prostatic fluid or healthy seminal plasma. Proteins (5 μ g) were separated by SDS-PAGE and then transferred to PVDF membrane. The membrane was probed with polyclonal anti-human-C5. (B) Proteolysis of C5 in the seminal plasma can be abrogated by a PSA inhibitor. Seminal plasma was supplemented with purified human C5 in the presence or absence of a PSA inhibitor. After a two hour incubation C5 levels were determined by Western blot with a polyclonal C5 antibody.